The recent introduction of novel treatments for advanced neuroendocrine tumors (NETs) and the well-established impact of clinical case discussion within dedicated multidisciplinary teams indicates the need to promote the centralization of rare diseases, such as NENs (neuroendocrine neoplasms). Data on the real-life use of and indications for [68Ga]Ga-DOTANOC PET/CT were collected from a prospective monocentric 5-year electronic archive including consecutive patients with confirmed and suspected NETs (September 2017 to May 2022). Overall, 2082 [68Ga]Ga-DOTANOC PET/CT scans (1685 confirmed NETs, 397 suspected NETs) were performed in 1537 patients. A high positivity rate was observed across different clinical settings (approximately 70%). Approximately 910/2082 scans were requested by the local oncology ward (851 confirmed NETs, 59 suspected NETs). The following observations were found: (i) the detection rate across all indications was 73.2% (higher for staging, peptide receptor radioligand therapy (PRRT) selection, and treatment response assessment); (ii) in suspected NETs, PET was more often positive when based on radiological findings. This systematic data collection in a high-volume diagnostic center represents a reliable cohort reflecting the global trends in the use of [68Ga]Ga-DOTANOC PET/CT for different clinical indications and primary tumor sites, but prompts the need for further multicenter data sharing in such a rare and slowly progressive disease setting.
近期针对晚期神经内分泌肿瘤（NETs）的新型疗法的引入，以及专业多学科团队内临床病例讨论所确立的显著影响，表明有必要推动如神经内分泌肿瘤（NENs）等罕见疾病的诊疗集中化。本研究从前瞻性单中心五年电子档案中收集了关于[68Ga]Ga-DOTANOC PET/CT在实际临床应用中的使用情况及适应症数据，该档案连续收录了确诊及疑似NETs患者（2017年9月至2022年5月）。总计对1537名患者进行了2082次[68Ga]Ga-DOTANOC PET/CT扫描（其中1685例为确诊NETs，397例为疑似NETs）。在不同临床场景中均观察到较高的阳性率（约70%）。约910/2082次扫描由本院肿瘤科申请（851例确诊NETs，59例疑似NETs）。主要发现如下：（1）所有适应症的总检出率为73.2%（在分期、肽受体放射性配体治疗筛选及疗效评估中检出率更高）；（2）对于疑似NETs病例，基于影像学发现进行PET检查时阳性率更高。这项在高容量诊断中心开展的系统性数据收集，构成了反映[68Ga]Ga-DOTANOC PET/CT在不同临床适应症及原发肿瘤部位应用全球趋势的可靠队列，但提示在此类罕见且进展缓慢的疾病领域中，需要进一步推动多中心数据共享。
肿瘤(癌症)患者之家